This week we bring to you four companies, namely Sunworks (NASDAQ: SUNW), Progenity Inc (NASDAQ: PROG), Upland Software Inc (NASDAQ: UPLD) and Purple Innovation Inc (NASDAQ: PRPL) that could turn out be to vulnerable investments, in view of the challenges being faced by these companies, such as...
“Realignment” of Management Team Rafael Holdings, Inc. (NYSE: RFL), announced the realignment of its management team, including the departure of the CEO Ameet Mallik, William Conkling, chief commercial and business officer and Ashok David Marin, chief legal officer among others. The responsibilities of the CEO will...
Termination of Collaboration with Roche Atea Pharmaceuticals, Inc. (NASDAQ: AVIR), a clinical-stage biopharmaceutical company, announced the termination of its strategic collaboration with Roche (OTCQX: RHHBY), for the joint development of AT-527, intended for the treatment of COVID-19. The agreement will be terminated on February 10,2022 and...
This week we bring to you four companies, namely Digital World Acquisition Corp (NASDAQ: DWAC), SmileDirectClub (NASDAQ: SDC), Remark Holdings Inc (NASDAQ: MARK) and PetMed Express (NASDAQ: PETS) that could turn out be to vulnerable investments, in view of the challenges being faced by these...
Cogent Biosciences, Inc. (NASDAQ: COGT) is a clinical-stage biotechnology company targeting underlying causes of genetic dysfunction that cause diseases such as cancers, autoimmune disorders and rare diseases. The Company’s lead candidate bezuclastinib (CGT9486), is a precision kinase inhibitor that inhibits the KIT D816V mutation, which...
Technology Industry has been focused on minimizing the impact of COVID-19 and marching ahead with its innovations and breakthroughs, be it critical security systems, innovative marketing solutions or cutting-edge data analytics and search technology. We take a look at some tech companies that are impervious to...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical focused on creating novel therapies for treatment of cancer, announced that a crucial phase 3 trial of QINLOCK in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib did not meet the primary endpoint of improved...
Clinical-Stage companies offer an exciting investment opportunity with massive upside potential. Most of these companies bring new and highly differentiated approaches, advanced scientific knowledge and a zeal for innovation to the table. Our biotech picks this week are making strides in fields such as immune-oncology, ocular...
BeyondSpring, Inc. (NASDAQ: BYSI) is a clinical-stage biopharmaceutical company focused on creating transformative treatments for immune-oncology conditions. The Company’s lead candidate is plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), which possess a unique mechanism of action and was evaluated in Phase 3 clinical trials in...
Oyster Point Pharma, Inc. (NASDAQ: OYST) is a commercial-stage biopharmaceutical company creating first-in-class therapies for the treatment of ophthalmic conditions. The Company’s lead product TYRVAYA, (varenicline solution) Nasal Spray 0.03 mg (formerly referred to as OC-01), has become the first and only FDA-approved nasal spray,...
